Drugs that target cholinesterases
作者： Ezio Giacobini
DOI: 10.1007/978-3-0348-7867-8_2
关键词: Vascular dementia 、 Physostigmine 、 Medicine 、 Apathy 、 Tricyclic 、 Cognition 、 Cholinesterase 、 Tacrine 、 Pharmacology 、 Alzheimer's disease
摘要: Currently, cholinesterase inhibitors (ChEI) represent the treatment of choice for Alzheimer’s disease (AD). Following introduction in 1980s a first generation drugs such as physostigmine and tacrine, second more suitable compounds was developed 1990s. These are clinically efficacious produce less severe side-effects at effective doses. Contrary to discovery other neurotransmitter-based CNS neuroleptics, tricyclic anti-depressants anxiolytics, clinical application ChEI cognitive deficits AD neither accidental nor serendipitous. Its rationale solidly founded on data derived from experimental physiology behavioral pharmacology cholinergic system animals humans. Clinical results effect these cognition (memory, attention concentration) recently symptoms (apathy, hallucinations motor agitation) confirmed predictions potential efficacy based laboratory data.
springer.com
sci-hub.st 参考文章(90)
John C. Morris, Martin R. Farlow, Steven H. Ferris, Alexander F. Kurz, Alfred Maelicke, Lee Rasmusen, David Wilkinson, Bing Yan, Panel discussion:recommendations for prescribers Clinical Therapeutics. ,vol. 23, ,(2001) , 10.1016/S0149-2918(01)80166-1
Thomas D. McRae, Elias M. Schwam, Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Current Medical Research and Opinion. ,vol. 18, ,(2002) , 10.1185/030079902125000949
T Rees, PI Hammond, H Soreq, S Younkin, S Brimijoin, Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiology of Aging. ,vol. 24, pp. 777- 787 ,(2003) , 10.1016/S0197-4580(02)00230-0
M. R. Farlow, P. A. Cyrus, A. Nadel, D. K. Lahiri, A. Brashear, B. Gulanski, Metrifonate treatment of AD influence of APOE genotype Neurology. ,vol. 53, pp. 2010- 2016 ,(1999) , 10.1212/WNL.53.9.2010
Magdolna Pakaski, Zoltan Rakonczay, Peter Kasa, Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro Neurochemistry International. ,vol. 38, pp. 219- 226 ,(2001) , 10.1016/S0197-0186(00)00091-7
S. L. Rogers, M. R. Farlow, R. S. Doody, R. Mohs, L. T. Friedhoff, , A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease Neurology. ,vol. 50, pp. 136- 145 ,(1998) , 10.1212/WNL.50.1.136
Mark Weiser, Heschi H. Rotmensch, Amos D. Korczyn, Richard Hartman, Ana Cicin-Sain, Ravi Anand, , A pilot, randomized, open‐label trial assessing safety and pharmakokinetic parameters of co‐administration of rivastigmine with risperidone in dementia patients with behavioral disturbances International Journal of Geriatric Psychiatry. ,vol. 17, pp. 343- 346 ,(2002) , 10.1002/GPS.599
Indra I. Angunawela, Andrew Barker, Anticholinesterase drugs for alcoholic Korsakoff syndrome International Journal of Geriatric Psychiatry. ,vol. 16, pp. 338- 339 ,(2001) , 10.1002/GPS.338
Francesca Mori, Chen-Ching Lai, Fabio Fusi, Ezio Giacobini, Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport. ,vol. 6, pp. 633- 636 ,(1995) , 10.1097/00001756-199503000-00012
E. A. Werber, J. M. Rabey, The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. Journal of Neural Transmission. ,vol. 108, pp. 1319- 1325 ,(2001) , 10.1007/S007020100008